Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...
The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results